ArticleBMC pediatrics2026
Metabolomic identification and analysis of potential biomarkers of febrile seizures.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunological mechanisms and prevention strategies for febrile seizures in children.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFebrile seizures (FS) represent the most common type of seizures in children; however, their exact pathogenesis remains incompletely understood. Currently, there is a lack of specific biomarkers for predicting FS occurrence, and existing prophylactic drug strategies remain controversial. Using untargeted metabolomics, this study investigates metabolic differences between children with FS and those with fever but without seizures (non-febrile seizures, NFS), aiming to elucidate the metabolic profile of FS and identify potential biomarkers, thereby providing new insights for clinical prediction and treatment.
methodsPlasma samples were collected from 31 children with FS and 31 children with NFS. Untargeted metabolomic profiling was performed using high-performance liquid chromatography coupled with high-resolution mass spectrometry (HPLC-HRMS). Peak extraction and metabolite identification were conducted with the XCMS software. Differential metabolites were screened using both univariate and multivariate statistical analyses, followed by metabolic pathway enrichment analysis. A random forest algorithm was applied to construct a predictive model, and significantly altered metabolites were selected as candidate biological predictors.
resultsChildren with FS exhibited significant metabolic disturbances across multiple pathways, including necroptosis, glycerophospholipid metabolism, linoleic acid metabolism, sphingolipid signaling, phagocytosis, ferroptosis, and sphingolipid metabolism. The random forest model identified 10 significantly altered metabolites as potential predictors: SM(d18:1/24:1), LysoPC(22:0/0:0), SM(d18:0/18:0), Cer(d18:1/16:0), LysoPC(24:0/0:0), 12,13-DHOME, diethanolamine, pantothenic acid, arachidonic acid, and 3-carbamoyl-2-phenylpropionaldehyde. The model demonstrated a predictive accuracy of 83% and achieved an area under the curve (AUC) of 0.98.
conclusionPatients with FS exhibited a distinct metabolic profile characterized by activated necroptosis, dysregulated lipid metabolism, and inflammatory imbalance. Metabolites such as arachidonic acid, lysophosphatidylcholines, and sphingolipids may serve as potential biomarkers and therapeutic targets. This study provides new metabolomic evidence for early prediction and targeted intervention of FS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.